Correction to “S-Enantiomer of the Antitubercular Compound S006-830 Complements Activity of Frontline TB Drugs and Targets Biogenesis of Mycobacterium tuberculosis Cell Envelope”

Padam Singh; Shashi Kant Kumar; Vineet Kumar Maurya; Basant Kumar Mehta; Hafsa Ahmad; Anil Kumar Dwivedi; Vinita Chaturvedi; Tejender S. Thakur; Sudhir Sinha

首页> 外文期刊>ACS Omega >Correction to “S-Enantiomer of the Antitubercular Compound S006-830 Complements Activity of Frontline TB Drugs and Targets Biogenesis of Mycobacterium tuberculosis Cell Envelope”

【24h】

Correction to “S-Enantiomer of the Antitubercular Compound S006-830 Complements Activity of Frontline TB Drugs and Targets Biogenesis of Mycobacterium tuberculosis Cell Envelope”

机译：对“抗结核化合物S006-830的S-对映体补充一线结核药物的活性并靶向结核分枝杆菌细胞包膜的生物发生”的修正

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Correction to page 8463. Under the Headings “Molecular Docking” and “Accession Codes”: The text (PDB ID: 3VIU) should be read as (PDB ID: 3V1U).

机译：对8463页的更正。在“分子对接”和“登录代码”标题下：文本（PDB ID：3VIU）应读为（PDB ID：3V1U）。

著录项

来源
《ACS Omega》 |2017年第12期|共1页
作者
Padam Singh; Shashi Kant Kumar; Vineet Kumar Maurya; Basant Kumar Mehta; Hafsa Ahmad; Anil Kumar Dwivedi; Vinita Chaturvedi; Tejender S. Thakur; Sudhir Sinha;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类化学;
关键词

相似文献

外文文献
中文文献
专利

1. Correction to “S-Enantiomer of the Antitubercular Compound S006-830 Complements Activity of Frontline TB Drugs and Targets Biogenesis of Mycobacterium tuberculosis Cell Envelope” [J] . Padam Singh, Shashi Kant Kumar, Vineet Kumar Maurya, ACS Omega . 2017,第12期

机译：对“抗结核化合物S006-830的S-对映体补充一线结核药物的活性并靶向结核分枝杆菌细胞包膜的生物发生”的修正
2. S-Enantiomer of the Antitubercular Compound S006-830 Complements Activity of Frontline TB Drugs and Targets Biogenesis of Mycobacterium tuberculosis Cell Envelope [J] . Padam Singh, Shashi Kant Kumar, Vineet Kumar Maurya, ACS Omega . 2017,第11期

机译：抗胆管化合物S006-830的S-映体补充了前线TB药物的活性，靶向靶的生物发生器 - 结核分枝杆菌（Cealcobacterium）细胞包膜
3. Progress in targeting cell envelope biogenesis in Mycobacterium tuberculosis [J] . JacksonM., McNeilM.R., BrennanP.J. Future microbiology . 2013,第7期

机译：结核分枝杆菌靶向细胞包膜生物发生的研究进展
4. Application of Factor Analysis on Mycobacterium Tuberculosis Transcriptional Responses for Drug Clustering, Drug Target, and Pathway Detections [C] . Jeerayut Chaijaruwanich, Jamlong Khamphachua, Sukon Prasitwattanaseree, International Conference on Advanced Data Mining and Applications(ADMA 2006); 20060814-16; Xi'an(CN) . 2006

机译：因子分析在结核分枝杆菌转录反应中用于药物聚类，药物靶标和途径检测的应用
5. Mining the Mycobacterium tuberculosis cellular envelope for diagnostic and drug targets. [D] . Wolfe, Lisa Marie. 2013

机译：挖掘结核分枝杆菌细胞包膜作为诊断和药物靶标。
6. Correction to S-Enantiomer of the AntitubercularCompound S006-830 Complements Activity of Frontline TB Drugs and TargetsBiogenesis of Mycobacterium tuberculosis Cell Envelope [O] . Padam Singh, Shashi Kant Kumar, Vineet Kumar Maurya, 2017

机译：对抗结核病的S-对映体的更正化合物S006-830可补充一线结核病药物和靶标的活性结核分枝杆菌细胞包膜的生物发生
7. Correction to “S-Enantiomer of the Antitubercular Compound S006-830 Complements Activity of Frontline TB Drugs and Targets Biogenesis of Mycobacterium tuberculosis Cell Envelope” [O] . Padam Singh, Shashi Kant Kumar, Vineet Kumar Maurya, 2017

机译：校正“抗结核化合物s006-830的s-对映体补充前线TB药物的活性和目标结核分枝杆菌细胞信封的生物发生”

Correction to “S-Enantiomer of the Antitubercular Compound S006-830 Complements Activity of Frontline TB Drugs and Targets Biogenesis of Mycobacterium tuberculosis Cell Envelope”

摘要

著录项

相似文献

相关主题

期刊订阅